Abstract:Abstract Aims Aortic aneurysm/dissection (AAD) is a life-threatening disorder lacking effective pharmacotherapeutic remedies. Aldehyde dehydrogenase 2 (ALDH2) polymorphism is tied with various risk factors for AAD including hypertension, atherosclerosis, and hypercholesterolaemia although direct correlation between the two remains elusive. Methods and results Two independent case–control studies were conducted involving 307 AAD patients and 399 healthy controls in two geographically distinct areas in China. Our data revealed that subjects carrying mutant ALDH2 gene possessed a ∼50% reduced risk of AAD compared with wild-type (WT) alleles. Using 3-aminopropionitrile fumarate (BAPN)- and angiotensin II (Ang II)-induced AAD animal models, inhibition of ALDH2 was found to retard development of AAD. Mechanistically, ALDH2 inhibition ablated pathological vascular smooth muscle cell (VSMC) phenotypical switch through interaction with myocardin, a determinant of VSMC contractile phenotype. Using microarray and bioinformatics analyses, ALDH2 deficiency was found to down-regulate miR-31-5p, which further altered myocardin mRNA level. Gain-of-function and loss-of-function studies verified that miR-31-5p significantly repressed myocardin level and aggravated pathological VSMC phenotypical switch and AAD, an effect that was blunted by ALDH2 inhibition. We next noted that ALDH2 deficiency increased Max expression and decreased miR-31-5p level. Moreover, ALDH2 mutation or inhibition down-regulated levels of miR-31-5p while promoting myocardin downstream contractile genes in the face of Ang II in primary human VSMCs. Conclusions ALDH2 deficiency is associated with a lower risk of AAD in patients and mice, possibly via suppressing VSMC phenotypical switch in a miR-31-5p-myocardin-dependent manner. These findings favour a role for ALDH2 and miR-31-5p as novel targets for AAD therapy.

Advances in Factors Affecting ALDH2 Activity and its Mechanisms

Aldehyde dehydrogenase 2 and arrhythmogenesis

The role of aldehyde dehydrogenase 2 in cardiovascular disease

Characterization of the Molecular Mechanisms Underlying Increased Ischemic Damage in the Aldehyde Dehydrogenase 2 Genetic Polymorphism Using a Human Induced Pluripotent Stem Cell Model System.

Targeting Acetaldehyde Dehydrogenase 2 (ALDH2) in Heart Failure-Recent Insights and Perspectives.

ALDH2 in alcoholic heart diseases: molecular mechanism and clinical implications.

Aldehyde Dehydrogenase-2 Roles in Ischemic Cardiovascular Disease.

Aldehyde Dehydrogenase 2-Associated Metabolic Abnormalities and Cardiovascular Diseases: Current Status, Underlying Mechanisms, and Clinical Recommendations

ALDH2 polymorphism and myocardial infarction: From alcohol metabolism to redox regulation

Impact of common ALDH2 inactivating mutation and alcohol consumption on Alzheimer's disease

Genotype of Ethanol Metabolizing Enzyme Genes by Oligonucleotide Microarray in Alcoholic Liver Disease in Chinese People.

ALDH2 and Stroke: A Systematic Review of the Evidence.

Origin and Spread of the ALDH2 Glu504Lys Allele

Aldehyde Dehydrogenases As Promising Targets for Treating Toxic Alde-hyde-related Diseases.

ALDH2 Rs671 Polymorphism and the Risk of Heart Failure with Preserved Ejection Fraction (hfpef) in Patients with Cardiovascular Diseases

The potential of aldehyde dehydrogenase 2 as a therapeutic target in cardiovascular disease

Mitochondrial Aldehyde Dehydrogenase in Myocardial Ischemia-Reperfusion Injury: from Bench to Bedside.

A common East-Asian ALDH2 mutation causes metabolic disorders and the therapeutic effect of ALDH2 activators

Prevention of aortic dissection and aneurysm via an ALDH2-mediated switch in vascular smooth muscle cell phenotype

Glu504Lys Single Nucleotide Polymorphism of Aldehyde Dehydrogenase 2 Gene and the Risk of Human Diseases

The role of acetaldehyde dehydrogenase 2 in the pathogenesis of liver diseases